CATX today
$0.94+$0.10 (+11.95%)close Nov 13, 2026Trend
DailyDowntrend (starting)
4 hourAscending Triangle
1 hourStrong Bullish
15 minStrong Bullish
5 minSymmetric Triangle
Daily trend turns up above $6.16
Key levels
Resistance$1.27
Resistance$1.06
Latest news & SEC filings
SEC FilingPerspective Therapeutics, Inc. filed an insider trading report (Form 4)
AnalystTruist Securities keeps Buy rating on Perspective Therapeutics, cuts target to $8
All CATX news →About Perspective Therapeutics
Perspective Therapeutics is a clinical-stage radiopharmaceutical company developing targeted alpha therapies for cancer. Its main programs use isotopes like Pb-212 to deliver radiation to tumor cells. The company also provides brachytherapy seeds for prostate cancer treatment through its subsidiary Isoray. It operates in the United States and runs clinical trials at leading cancer hospitals.
Based on the company's 10-K filed Mar 16, 2026.
NYSE · Healthcare
Perspective Therapeutics, Inc. (CATX)
What Is the Price Target for CATX?
SEPT Low Target
$4.00
SEPT Mid Target
$4.50
SEPT High Target
$5.00
Analyst Consensus
$4.50
Is CATX a Buy or Sell Right Now?
Thesis
- •Revenue growing -86.7% YoY with UNKNOWN trend — consistent growth.
AI-Powered Trading Signals
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy for CATX.
Start Free Trial →Is CATX Overvalued or Undervalued?
Valuation Verdict
UNDERVALUED
Methods Used
P/B, Analyst Consensus
Fair Value
$5.11
12
Moat Score
NONE
1/9
Piotroski Score
-2.0
Altman Z-Score
What Is Smart Money Doing with CATX?
Insider Signal
SELLING
0 buys / 7 sells (90d)
Congress Signal
NEUTRAL
0 buys / 0 sells (90d)
Institutional
N/A
Short Squeeze Risk
HIGH
Signal: HIGH_SHORT_INTEREST
Recent Insider Activity
| Name | Title | Type | Shares | Value | Date |
|---|---|---|---|---|---|
| Spoor Johan M. | director officer | Buy | 47,000 | $38K | Nov 11, 2026 |
| Lantheus Alpha Therapy, LLC | 10% owner | Sale | 167,149 | $526K | Sep 4, 2026 |
| Lantheus Alpha Therapy, LLC | 10% owner | Sale | 80,783 | $251K | Sep 3, 2026 |
| Lantheus Alpha Therapy, LLC | 10% owner | Sale | 42,129 | $131K | Sep 2, 2026 |
| Lantheus Holdings, Inc. | 10% owner | Sale | 35,769 | $112K | Sep 1, 2026 |
| Lantheus Alpha Therapy, LLC | 10% owner | Sale | 35,769 | $112K | Sep 1, 2026 |
| Lantheus Holdings, Inc. | 10% owner | Sale | 78,145 | $246K | Aug 31, 2026 |
| Lantheus Alpha Therapy, LLC | 10% owner | Sale | 78,145 | $246K | Aug 31, 2026 |
Track Smart Money Across 4,000+ Stocks
Insider trades, congress trades, institutional flows, and short interest — updated daily with real-time alerts.
See All Smart Money Signals →CATX Growth Story
Revenue YoY
-86.7%
3yr Revenue CAGR
N/A%
EPS Growth YoY
-13.82%
FCF Growth YoY
-31.0%
Revenue Trend
UNKNOWN
Dark Pool Trades for CATX
PREVIEWSEPT Investing tracks real-time dark pool institutional trades for CATX, including block trade sizes, dollar values, and buy/sell side classification. Dark pool trades reveal where institutional investors are positioning before moves become visible on public exchanges.
| Time | Price | Size | Value | Side |
|---|---|---|---|---|
| 20:59:56 | $0.95 | 6,000 | $$6K | BUY |
| 20:59:06 | $0.95 | 2,217 | $$2K | SELL |
| 20:59:02 | $0.95 | 1,100 | $$1K | MIDPOINT |
| 20:59:02 | $0.95 | 2,300 | $$2K | SELL |
| 20:58:22 | $0.95 | 1,700 | $$2K | SELL |
5 dark pool trades shown · $$13K preview volume
Real-time institutional flow, block trades, and net positioning
Full AI Research Report
SEPT's Trading AI has generated a free, downloadable PDF research report for Perspective Therapeutics, Inc. (CATX) covering valuation analysis, financial health assessment, growth projections, smart money tracking, earnings and key price levels. For research only, not investment advice.
Report includes: PDF download, detailed valuation models (DCF, P/E, EV/EBITDA), institutional flow analysis, congress and insider trade tracking, FinBERT news sentiment (2 articles analyzed), and SEC filing intelligence...
AI-Powered Trading Signals.
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy. SEPT tells you when to buy, when to sell, and grades every stock so you never trade blind.
Try SEPT Free for 7 Days →CATX — frequently asked questions
What is CATX stock price today?
Perspective Therapeutics, Inc. (CATX) is at $0.94, up 11.95% (+$0.10) at the Nov 13, 2026 close.
Why is CATX stock moving today?
Latest CATX news — Nov 13, 2026: Perspective Therapeutics, Inc. filed an insider trading report (Form 4) · Nov 10, 2026: Truist Securities keeps Buy rating on Perspective Therapeutics, cuts target to $8
Why did CATX stock move on Oct 26, 2026?
Perspective Therapeutics (CATX) shares fell 14.64% today, closing at $1.20 after opening at $1.40 and trading between a high of $1.59 and a low of $1.11 on volume of over 9.4 million shares. The decline followed RBC Capital downgrading the stock to Sector Perform and lowering its price target to $4, reflecting a less favorable view of the shares.
What is the CATX price target?
The average analyst price target for CATX is $4.50, ranging from $4 to $5, based on 2 analysts. Latest: RBC Capital downgrade on Oct 26, 2026.
What do analysts rate CATX?
Analyst ratings for CATX: 0 Buy, 9 Hold, 2 Sell — consensus Hold.
Did CATX beat earnings?
CATX last reported on Aug 10, 2026: EPS -$0.22 vs -$0.25 expected — a beat of 12.4%.
Does CATX pay a dividend?
CATX does not currently pay a dividend.
How much debt does CATX have?
Perspective Therapeutics, Inc. reported $2M of debt and $48M of cash (Jun 30, 2026).
What are CATX support and resistance levels?
Resistance: $1.06, $1.27, $1.75.
What are insiders doing with CATX?
Insider activity: SELLING, 0 buys and 7 sells in the last 90 days.
What is the latest news on CATX?
Nov 13, 2026: Perspective Therapeutics, Inc. filed an insider trading report (Form 4) · Nov 10, 2026: Truist Securities keeps Buy rating on Perspective Therapeutics, cuts target to $8